NCT06970353View on ClinicalTrials.gov

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2031

Conditions
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Interventions
DRUG

Tunlametinib

Locally advanced or metastatic radioactive iodine refractory NRAS mutant differentiated thyroid cancer

DRUG

Tunlametinib+PD-1 mAb

Locally advanced or metastatic NRAS mutant poor-differentiated, undifferentiated thyroid cancer

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06970353 - Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter